NeuroRisk.aiRequest Access →
biological · Product Intelligence

Pembrolizumab
Pipeline Intelligence

Pembrolizumab: 26 indexed trials, 3 sponsors; 0 linked Orange Book patents and 0 FDA-linked events where matched.

Request product intelligence brief →
⚗
26Indexed trials
▦
3Sponsors
⌁
0Orange Book patent links
◎
0FDA-linked events

Development evidence

NCT02255097Merck Sharp & Dohme LLC · parkinsonsPHASE2
NCT02564263Merck Sharp & Dohme LLC · parkinsonsPHASE3
NCT02622074Merck Sharp & Dohme LLC · parkinsonsPHASE1
NCT02964013Merck Sharp & Dohme LLC · parkinsonsPHASE1
NCT03066778Merck Sharp & Dohme LLC · parkinsonsPHASE3
NCT03221426Merck Sharp & Dohme LLC · parkinsonsPHASE3
NCT03358472Incyte Corporation · parkinsonsPHASE3
NCT03361228Incyte Corporation · parkinsonsPHASE1,PHASE2
NCT03615326Merck Sharp & Dohme LLC · parkinsonsPHASE3
NCT03631407Merck Sharp & Dohme LLC · parkinsonsPHASE2
NCT03834506Merck Sharp & Dohme LLC · parkinsonsPHASE3
NCT04003636Merck Sharp & Dohme LLC · parkinsonsPHASE3
NCT04191096Merck Sharp & Dohme LLC · parkinsonsPHASE3
NCT04191135Merck Sharp & Dohme LLC · parkinsonsPHASE2
NCT04220892Jose Carrillo · neuro_oncologyEARLY_PHASE1

FDA / patent evidence

No FDA Orange Book product match is asserted for this intervention.

Regulatory context

FDA Orange Book coverage is U.S.-specific and is not a substitute for worldwide patent or regulatory review.